Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer

Cancer is the second leading cause of death and there is an urgent need to improve cancer management. We have developed an innovative cancer therapy named nergistic I muno tothermal anotherap (SYMPHONY) by combining gold nanostars (GNS)-mediated photothermal ablation with checkpoint inhibitor immuno...

Full description

Saved in:
Bibliographic Details
Published in:Nanophotonics (Berlin, Germany) Germany), 2021-09, Vol.10 (12), p.3295-3302
Main Authors: Liu, Yang, Chorniak, Ericka, Odion, Ren, Etienne, Wiguins, Nair, Smita K., Maccarini, Paolo, Palmer, Gregory M., Inman, Brant A., Vo-Dinh, Tuan
Format: Article
Language:English
Subjects:
Ablation
Cancer
Gold
gold nanostars
Immunotherapy
photoimmunotherapy
Plasmonics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer is the second leading cause of death and there is an urgent need to improve cancer management. We have developed an innovative cancer therapy named nergistic I muno tothermal anotherap (SYMPHONY) by combining gold nanostars (GNS)-mediated photothermal ablation with checkpoint inhibitor immunotherapy. Our previous studies have demonstrated that SYMPHONY photoimmunotherapy not only treats the primary tumor but also dramatically amplifies anticancer immune responses in synergy with checkpoint blockade immunotherapy to treat remote and unresectable cancer metastasis. The SYMPHONY treatment also induces a ‘cancer vaccine’ effect leading to immunologic memory and prevents cancer recurrence in murine animal models. This manuscript provides an overview of our research activities on the SYMPHONY therapy with plasmonic GNS for cancer treatment.
ISSN:2192-8614
2192-8606
2192-8614
DOI:10.1515/nanoph-2021-0237